Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

RIVKAL clinical trial for the first-in-human administration of BIM2b in participants with Glioblastoma Pending

2023-508662-15-00 Glioblastoma 1
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCL… Pending

2025-520792-67-00 Patients with advanced, metastatic NSCLC that have not 5
Prospective feasibility pilot study evaluating the value of [68Ga]Ga-PENTIXAFOR PET-CT in patients with locally advanced or metastatic Small… Pending

2024-514057-30-00 cell lung carcinoma 3
An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osi… Pending

2024-519071-25-00 Advanced NSCLC 3
Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma w… Pending

2025-521437-88-00 head and neck squamous cell carcinoma 4
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and … Pending

2025-521989-95-00 Advanced/Metastatic Non-squamous Non-Small Cell Lung Ca 9
A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced… Pending

2025-521438-27-00 advanced, unresectable and/or metastatic solid tumors 1
ABT-199 (Venetoclax) and Purine analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (ApoAML… Pending

2024-510717-15-00 Acute myeloid leukemia 9
A randomized trial of systemic chemotherapy with or without hepatic arterial infusion pump chemotherapy for patients with inoperable bile du… Pending

2024-518065-10-00 Unresectable intrahepatic cholangiocarcinoma 4
Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancer. Pending

2024-518570-13-00 Resectable peritoneal metastases of a colorectal origin 10
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5
A study of Mirdametinib in Infants and Toddlers under 24months of age with Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas… Pending

2025-522000-24-00 Neurofibromatosis Type 1 (NF1) Associated Plexiform Neu 3
A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending

2024-512195-35-00 Stage I adenocarcinoma non-small cell lung cancer (NSCL 5
CAT-01 Pending

2024-517594-24-01 Cervical carcinoma 9
Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System and verteporfin for injection for the tr… Pending

2024-519658-35-00 Primary localised prostate cancer 9
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Pending

2024-519087-41-00 Breast cancer is the most common form of cancer among w 5
Individualized everolimus therapy in metastatic breast cancer Pending

2023-505590-33-06 metastatic breast cancer 4
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temo… Pending

2025-520814-78-00 Diffuse Midline Glioma, H3K27-altered 9
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending

2025-522019-40-00 relapsed or refractory BCR::ABL1-positive (Philadelphia 9
Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS Pending

2025-523396-38-00 Relapse or refractory (r/r) acute myeloid leukaemia (AM 9
A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending

2025-524241-27-00 Treatment-naїve mantle cell lymphoma (MCL) 5
Beamion 44: A study to test how well zongertinib is tolerated by people with advanced non-small cell lung cancer with HER2 mutations when gi… Recruiting

2025-523567-38-00 locally advanced or metastatic NSCLC 4 2026-06-02
SIE-1 Recruiting

2025-523269-31-00 Hormone receptor-positive early breast cancer in post-m 3 2026-06-02